System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD3

OKT3 (IgG2a)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-631-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  12-631-C100 low endotoxin 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  12-631-M001 low endotoxin 1.0 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD3 complex is crucial in transducing antigen-recognition signals into the cytoplasm of T cells and in regulating the cell surface expression of the TCR complex. T cell activation through the antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3 gamma, CD3 delta, CD3 epsilon and CD3 zeta. These CD3 subunits are structurally related members of the immunoglobulins super family encoded by closely linked genes on human chromosome 11. The CD3 components have long cytoplasmic tails that associate with cytoplasmic signal transduction molecules. This association is mediated at least in part by a double tyrosine-based motif present in a single copy in the CD3 subunits. CD3 may play a role in TCR-induced growth arrest, cell survival and proliferation.
The CD3 antigen is present on 68-82% of normal peripheral blood lymphocytes, 65-85% of thymocytes and Purkinje cells in the cerebellum. It is never expressed on B or NK cells. Decreased percentages of T lymphocytes may be observed in some autoimmune diseases.

Specificity

The mouse monoclonal antibody OKT3 recognizes the CD3 antigen of the TCR/CD3 complex on mature human T cells. This antibody, also known as Orthoclone OKT3 or Muromonab-CD3, has been extensively used as a drug for therapy of acute, glucocorticoid resistant rejection of allogenic renal, heart and liver transplants. It has also been investigated for use in treating T-cell acute lymphoblastic leukemia.
HLDA VI; WS Code T6T-R3

Regulatory Status

Immunogen

Commercially sensitive information

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
    Recommended dilution: 1 μg/ml
  • Immunohistochemistry (frozen sections)
  • Functional Application
    counteracting both generation and function of effector T cells
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Smith SL: Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord. 1996 Sep;6(3):109-19; quiz 120-1. [Abstract]
  • *Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S: MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 1996 Sep 15;56(18):4205-12. [Abstract] [Full Text]
  • *Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS: Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 2003 Oct;17(10):1973-80. [Abstract]
  • *Undale AH, van den Elsen PJ, Celis E: Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol. 2004 Oct;16(10):1523-33. [Abstract] [Full Text]
  • *Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, Schwarz EC, Hoth M: T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14418-23. [Abstract] [Full Text]
  • *Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV, Badley AD. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol. 2005 Aug;79(15):9821-30. [Abstract] [Full Text]
  • *Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T: Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003 Feb 15;101(4):1630-6. [Abstract] [Full Text]
  • *Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, Klingebiel T: OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol. 2000 Nov;111(2):668-73. [Abstract]
  • *Gordon PR, Leimig T, Mueller I, Babarin-Dorner A, Holladay MA, Houston J, Kerst G, Geiger T, Handgretinger R: A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 2002 Jul;30(2):69-74. [Abstract] [Full Text]
  • *Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L: Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull. 2010 Jan;33(1):40-6. [Abstract]
  • *And many other.
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy